Association of FcγRIIIA Polymorphism and THPO Expression With Response to Eltrombopag in Refractory ITP Patients
Status:
Unknown status
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disease characterized by
antibody-mediated platelet destruction. The complex pathogenesis of ITP with multiple
challenges to immune system in terms of genetic predisposition, infection, responsiveness to
immunosuppressive therapy (IST) and inhibition of platelet production has proven the
diversity of constraints in diagnosing and treating ITP. Thrombopoietin receptor agonist
(Eltrombopag) is specifically indicated for the treatment of thrombocytopenia in patients
with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient
response to corticosteroids, immunoglobulins, or splenectomy. This clinical trial aims to
investigate the association of Fc gammaRIIIA gene (V158F) genetic predisposition with
treatment outcome of Immune Thrombocytopenia (ITP) in refractory ITP patients and especially
with Eltrombopag.
Phase:
Phase 3
Details
Lead Sponsor:
Armed Forces Bone Marrow Transplant Center, Rawalpindi, Pakistan National Institute of Blood and Marrow Transplant (NIBMT), Pakistan